Category: Biotech
Breaking News: @NutraPharma  $NPHC – CEO @Rikdeitsch Interviewed by @StockGuruDotCom
Chimerix to Present at the Morgan Stanley Global Healthcare Conference
Lot’s of Buzz coming from $CTIX – Cellceutix Corp.
MacroGenics to Participate in Two Upcoming Investor Conferences
Vital Therapies Announces Workforce and Cost Reduction Plans to Conserve Capital for a Possible New Clinical Trial

Spectranetics Names Stacy McMahan Chief Financial Officer

COLORADO SPRINGS, Colo., Aug. 27, 2015 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (NASDAQ:SPNC) today announced that Stacy McMahan has been named Chief Financial Officer, effective September 28, 2015. In this role, Ms. McMahan will report directly to Scott Drake, President and Chief Executive Officer.Ms. McMahan has more than 25 years of finance leadership experience, including…

Portola Pharmaceuticals to Present Preclinical Data with Andexanet Alfa and Factor Xa Inhibitor Edoxaban at European Society of Cardiology Congress 2015

SOUTH SAN FRANCISCO, Aug. 27, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq: PTLA) today announced that results of a preclinical study of andexanet alfa will be presented in a moderated poster session at the European Society of Cardiology (ESC) 2015 Congress in London, U.K. The study assessed the activity of andexanet alfa in reversing anticoagulation…
Trade Alert: Ekso Bionics Holdings, Inc. Strong Volume Driving Stock Upward
Top Five BioTech Stocks With News Out Recently

Notch3 Biomarker Results and Updated Data From OncoMed’s Phase 1b/2 PINNACLE Clinical Trial Accepted for Presentation at the 16th World Conference on Lung Cancer

REDWOOD CITY, Calif., Aug. 27, 2015 (GLOBE NEWSWIRE) -- New biomarker data related to OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) Phase 1b/2 PINNACLE clinical trial of tarextumab (Anti-Notch 2/3, OMP-59R5) in small cell lung cancer (SCLC) will be presented by academic collaborator, Anne Chiang M.D., Ph.D., of the Yale School of Medicine, during a mini oral discussion…
Westmead Hospital Research Provides Significant Data Supporting the Ablation Effectiveness of Stereotaxis Magnetic Navigation

AGTC Announces Achievement of XLRS Patient Enrollment Milestone in Biogen Collaboration

GAINESVILLE, Fla., Aug. 27, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced it had met a patient enrollment milestone in the X-Linked Retinoschisis (XLRS) clinical study, which will earn AGTC a $5…
Amarantus Moves Annual Meeting Date Forward to September 2, 2015